Efficacy of the Multidisciplinary Treatment to the Quality of Life of With Functional Movement Disorders

Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (Other)
Overall Status
Recruiting
CT.gov ID
NCT05634486
Collaborator
Fundación Caser (Other)
40
1
2
10.5
3.8

Study Details

Study Description

Brief Summary

Randomized-clinical trial of multidisciplinary approach versus psychoeducation in patients with functional movement disorders: impact to their quality of life and their caregivers' quality of life. Patients with functional movement disorders are randomized in two arms of a one-month treatment (physiotherapy + cognitive-behavioral therapy versus psychoeducational as sham intervention) with a 3-month and 5-month follow-up where the investigators will measure the change in the patients' and caregivers' quality of life. Movement disorders specialists will review the severity of symptoms as blinded raters in the 3th-month and 5th-month follow-up.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)
  • Other: Psychoeducation (Sham intervention)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
40 patients with functional movement disorders will be randomized into two arms of treatments: a one-month multidisciplinary treatment (physiotherapy + cognitive-behavioral therapy) versus a one-month psychoeducation sham intervention (control group).40 patients with functional movement disorders will be randomized into two arms of treatments: a one-month multidisciplinary treatment (physiotherapy + cognitive-behavioral therapy) versus a one-month psychoeducation sham intervention (control group).
Masking:
Single (Investigator)
Masking Description:
Movement disorders specialists will review the severity of symptoms as blinded raters in the 3th-month and 5th-month follow-up.
Primary Purpose:
Treatment
Official Title:
Efficacy Study of the Multidisciplinary Therapeutic Approach to the Quality of Life of Patients With Functional Movement Disorders and Their Caregivers
Actual Study Start Date :
Jun 15, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Multidisciplinary therapeutic approach

Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist). 12 physiotherapy sessions during one month (three 60-minute sessions per week) administered by a physiotherapist with experience in functional neurological disorders. 4 cognitive-behavioral therapy sessions during one month (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy.

Behavioral: Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)
Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment

Sham Comparator: Psychoeducation

Diagnosis of Functional Movement Disorders by one of the PI (Movement Disorders Specialist). 4 psychoeducational sessions (one 60-minute intervention per week) administered by a psychologist with experience in cognitive-behavioral therapy.

Other: Psychoeducation (Sham intervention)
Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.

Outcome Measures

Primary Outcome Measures

  1. Quality of Life in patients with functional movement disorders measured by The 5-level EQ-5D version (EQ-5D-5L) - EQ visual analogue scale [3th-month and 5th-month follow-ups]

    Change in the patients' quality of life measured by changes in EQ-5D-5L - the EQ visual analogue scale (EQ VAS).

  2. Quality of Life in patients with functional movement disorders measured by The 5-level EQ-5D version (EQ-5D-5L) - EQ-5D descriptive system. [3th-month and 5th-month follow-ups]

    Change in the patients' quality of life measured by changes in EQ-5D-5L - EQ-5D descriptive system. The digits for the five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) can be combined into a 5-digit number that describes the patient's health state.

  3. Quality of Life in patients with functional movement disorders measured by the 36-Item Short Form Health Survey (SF-36) [3th-month and 5th-month follow-ups]

    Change in the patients' quality of life measured by changes in SF-36

Secondary Outcome Measures

  1. Quality of Life in caregivers of patients with functional movement disorders [3th-month and 5th-month follow-ups]

    Change in the caregivers' quality of life measured by changes in the Zarit Caregiver Burden Interview

  2. Severity of functional neurological symptoms of patients with functional movement disorders measured by Clinical Global Impressions (CGI) Scale [3th-month and 5th-month follow-ups]

    Change in the patients' symptoms severity measured by changes in the Clinical Global Impressions (CGI) Scale - Severity

  3. Improvement of functional neurological symptoms of patients with functional movement disorders [3th-month and 5th-month follow-ups]

    Improvement of the patients' symptoms severity measured by the Clinical Global Impressions (CGI) Scale - Improvement

  4. Severity of functional neurological symptoms of patients with functional movement disorders [3th-month and 5th-month follow-ups]

    Change in the patients' symptoms severity measured by changes in the simplified-Functional Movement Disorders Rating Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Functional Movement Disorders (Espay and Lang, 2015)

  • Patients should be 18 years old or older and capable of giving consent to freely and willingly participate in the study.

  • Patients should be able to attend the one-month ambulatory regime and follow-up visits.

Exclusion Criteria:
  • Any condition that avoid the patient from giving free consent to participate in the study.

  • Any non-controlled psychiatric disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitario Virgen del Rocío / Instituto de Biomedicina de Sevilla (IBiS) Sevilla Spain 41013

Sponsors and Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
  • Fundación Caser

Investigators

  • Principal Investigator: Pablo Mir, MD, PhD, Hospital Universitario Virgen del Rocío / Instituto de Biomedicina de Sevilla (IBiS)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
ClinicalTrials.gov Identifier:
NCT05634486
Other Study ID Numbers:
  • 1633-N-21
First Posted:
Dec 2, 2022
Last Update Posted:
Dec 2, 2022
Last Verified:
Nov 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2022